Anti-HIV agents: A step towards future

International Journal of Pharmaceutical Sciences Review and Research

Volumn 3, Issue 2, 2010, Pages 10-18

  Thakur, Devendra Singh ^a   Behera, Chinmay Kumar ^a   Patidar, Ajay ^a   Kumar, Pramod ^a   Kumar, Peeyush ^a   Lal, Champa ^a  

^a GURU GHASIDAS UNIVERSITY   (India)

Author keywords

AIDS; CCR5; Integrase inhibitors; Natural anti HIV agent

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APLAVIROC; ATAZANAVIR; CALANOLIDE A; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; IBALIZUMAB; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; MICHELLAMINE B; NAVELBINE; NELFINAVIR; NEVIRAPINE; PROSTRATIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CYSTITIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GENE THERAPY; HEART MUSCLE ISCHEMIA; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LIFE CYCLE; LIVER TOXICITY; MACROPHAGE; NANOTECHNOLOGY; NAUSEA; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA TRANSLATION; STRUCTURE ANALYSIS; VIRUS ENVELOPE; VIRUS REPLICATION;

EID: 79952021263     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg C M, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, and Hahn BH, Origin of HIV-1 in the chimpanzee pantroglodytes troglodytes, Nature, 397, 1999,436-441.
2. Keele BF, van Heuverswyn F., Li YY, Bailes E., Takehisa J, Santiago M L, Bibollet-Ruche F, Chen Y, Wain LV, Liegois F, Loul S, Mpoudi Ngole E, Bienvenue, H., et al., Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1, 3, 2006,5-25.
3. Huerta-Reyes M, Basualdo Mdel C, Abe F, Jimenez- Estrada M, Soler C, Reyes-Chilpa, R., HIV-1 inhibitory compounds from Calophyllum brasiliensis leaves. Biol. Pharm. Bull. 27 (9), 2004, 1471-1475.
4. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons, JAMA 288,2002,181-188.
5. Schering,Plough, Expands vicriviroc phase II study in treatment-naïve patients with HIV, http:/www.scheringplough.com/newsarticle.aspx?regidZ1307827 [accessed 12.09.09].
6. Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, et al. Piperazine-Based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1- [(4,6-Dimethyl-5-pyrimidi-nyl)carbonyl]- 4-[4-{2- methoxy-1(R)- 4-(trifluoromethyl)phe nyl}ethyl-3(S)- methyl-1-piperazinyl]- 4-methylpiperidine(Sch- 417690/Sch-D), a potent, highly Selective, and orally Bioavailable CCR5 antagonist, J Med Chem, 47,2004,2405-2408.
7. Cao YJ, Flexner CW, Dunaway S, Park JG, Klingman K, Wiggins I, et al. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrob Agents Chemother, 52, 2008, 1630-1634.
8. Esposito D, Craigie R. HIV integrase structure and function. Adv Virus Res, 52, 1999, 319-333.
9. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatmentnaive and treatment-experienced patients. J Acquir Immune Defic Syndr; 19, 2006, 1-5.
10. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137), J Virol, 82,2008, 764-774.
11. Gu S, Ji J, Kim JD, Yee JK, Rossi JJ, Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs. Oligonucleotides 16, 2006, 287-295.
12. Jakobsen MR, Haasnoot J, Wengel J, Berkhout B, Kjems J, Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology, 9,2007, 264.
13. Lebars I, Richard T, Di Primo C, Toulme JJ. LNA derivatives of a kissing aptamer targeted to the transactivating responsive RNA element of HIV-1. Blood Cells Mol Dis 38, 2007, 204-209.
14. Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, Rossi J, Dropulic B. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol, 78, 2004, 7079-7088.
15. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the antiCD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis, 189, 2004, 286-291.
16. Zhang XQ, Sorensen M, Fung M, Schooley RT, Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother, 50, 2006, 2231-2233.
17. Richter S, Parolin C, Gatto B, Del Vecchio C, Brocca- Cofano E, Fravolini A, et al. Inhibition of human immunodeficiency virus type 1 tat-trans-activationresponsive region interaction by an antiviral quinolone derivative. Antimicrob Agents Chemother, 48, 2004, 1895-1899.
18. Yang M, Discoveries of TateTAR interaction inhibitors for HIV-1. Curr Drug Targets Infect Disord, 5, 2005, 433-444.
19. Yuan D, He M, Pang R, Lin SS, Li Z, Yang M. The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 TateTAR inhibitors. Bioorg Med Chem 15, 2007, 265-272.
20. Vyas TK, Shah L, Amiji MM, Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv. 3(5), 2006, 613-628.
21. Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ, Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophagetargeted peg-fmlf (n-formyl-methionyl-leucylphenylalanine) nanocarriers for improving HIV drug delivery. Pharm. Res. 24(11), 2007, 2110-2119
22. Nowacek A, Gendelman HE, Nanoart, neuro AIDS and CNS drug delivery. Nanomed. 4(5), 2009, 557-574.
23. Farokhzad OC, Langer R, Impact of nanotechnology on drug delivery. ACS Nano 3(1), 2009, 16-20.
24. Davis ME, Chen ZG, Shin DM, Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 2008, 771-782.
25. Amiji MM, Vyas TK, Shah LK, Role of nanotechnology in HIV/AIDS treatment: Potential to overcome the viral reservoir challenge. Discov. Med. 6(34), 2006, 157-162.
26. Baert L, van't Klooster G, Dries W et al.: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (tmc278) for HIV treatment. Eur. J. Pharm. Biopharm. 72(3), 2009, 502-508.
27. Dou H, Destache CJ, Morehead JR et al.: Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108(8), 2006, 2827-2835.
28. Dou H, Morehead J, Destache CJ et al.: Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358(1), 2007, 148-158.
29. Dou H, Grotepas CB, McMillan JM et al.:Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183(1), 2009, 661-669.
30. Garg M, Asthana A, Agashe HB, Agrawal GP, Jain NK: Stavudine-loaded mannosylated liposomes: Invitro anti-HIV-activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 58(5), 2006, 605-616.
31. Garg M, Dutta T, Jain NK, Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm 67(1), 2007, 76-85.
32. Garg M, Garg BR, Jain S et al.: Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral effcacy of stavudine loaded 99mtc labeled galactosylated liposomes. Eur. J. Pharm. Sci, 33(3), 2008, 271-281.
33. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK, Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz tohuman monocytes/macrophages in vitro. J. Drug Target 15(1), 2007, 89-98.
34. Dutta T, Garg M, Jain NK, Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIVinfected macrophages in vitro. Eur. J. Pharm. Sci. 34(2-3), 2008, 181-189.
35. Wan L, Zhang X, Pooyan S et al.: Optimizing size and copy number for PEG-FMLF (n-formylmethionyl- leucyl-phenylalanine) nanocarrier uptake by macrophages. Bioconjug. Chem, 19(1), 2008, 28-38.
36. Elechiguerra JL, Burt JL, Morones JR et al.: Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnology 3, 2005, 6.
37. Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM: Silver nanoparticles fabricated in hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem. Commun. (40), 2005, 5059-5061.
38. Eguchi A, Meade BR, Chang YC et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27(6), 2009, 567-571.
39. Song E, Zhu P, Lee SK et al.: Antibody mediated in vivo delivery of small interfering RNAS via cellsurface receptors. Nat. Biotechnol. 23(6), 2005, 709-717.
40. Liu Z, Winters M, Holodniy M, Dai H: Sirna delivery into human t cells and primary cells with carbonnanotube transporters. Angew. Chem. Int. Ed. 46(12), 2007, 2023-2027.
41. Weber N, Ortega P, Clemente MI et al. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control Release 132(1), 2008, 55-64.
42. Kumar P, Ban HS, Kim SS et al. T cell-specifc siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134(4), 2008, 577-586.
43. Aline F, Brand D, Pierre J et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbe on surfactant-free anionic pla nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 27(38), 2009, 5284-5291.
44. Lori F, Calarota SA, Lisziewicz J, Nanochemistrybased immunotherapy for HIV-1. Curr. Med. Chem. 14(18), 2007, 1911-1919.
45. Fairman J, Moore J, Lemieux M et al. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum. Vaccin. 5(2), 2008, 3.
46. Burke B, Gomez-Roman VR, Lian Y et al. Neutralizing antibody responses to subtype b and c adjuvanted HIV envelope protein vaccination in rabbits. Virology 387(1), 2009, 147-156
47. Kim RM, Rouse EA, Chapman KT, Schleif WA, Olsen DB, Stahlhut M, Rutkowski CA, Emini EA and Tata JR. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1. Bioorg. Med. Chem. 14, 2004, 4651-4654.
48. Erik De Clercq, Anti-HIV drugs: 25 compounds approved within 25 years after the discovery (Review), International Journal of Antimicrobial Agents 33, 2009, 307-320.
49. S. Fu Lu, B. Chen, D. Davey, L. Dunning, S. Jaroch, K. May, J. Onuffer, G. Phillips, B. Subramanyam, J. Tseng, R. G. Wei, M. Wei and B. Ye, Bioorg. Med. Chem. Lett. 17 2007, 1883-1887.
50. Cumming JG, Brown SJ, Cooper AE, Faull AW, Flynn AP, Grime K, Oldfield J, Shaw JS, et al. Bioorg. Med. Chem. Lett. 16, 2006, 3533-3536.
51. Imamura S, Kurasawa O, Nara Y, Ichikawa T, Nishikawa Y, Iida T, Hashiguchi S, Kanzaki N, et al. Bioorg. Med. Chem, 12, 2004, 2295-2306.
52. Shankaran K, Donnelly KL, et al., Bioorg. Med. Chem. Lett, 14, 2004, 3419-3424.